QUICK LINKS
MAIN MENU
CONNECT WITH US

Clinical Trial Details

Title
A Randomized, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCI) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors CAMELLIA
Study Purpose
The main purpose of this research study is to assess whether lorcaserin HCl (brand name BELVIQ®) affects the risk of developing cardiovascular diseases in men and women at higher risk of developing these diseases.
Study Plan
Subjects will be randomized to study drug or placebo.
Investigators

Principal Investigator
Dominick J. Angiolillo, M.D., Ph.D., FACC
Medicine

Sub Investigator
Theodore A. Bass, M.D.
Medicine

Sub Investigator
Martin "M" Zenni, M.D.
Medicine

Meeting Schedule & Submission Deadlines

Note: All submissions for IRB review require a single electronic copy of all documents to be emailed and a single (signed) original hardcopy be provided to the IRB office. The IRB cannot log in the submission until the paper copy is received.

Resources

News & Announcements

COMJ faculty mourn loss of esteemed colleague  - Thumb

COMJ faculty mourn loss of esteemed colleague

7/21/2017

Robert Wears, MD, PhD, was regarded as an expert in patient safety As faculty members toggle grief and shock over the death of Robert... [full story]

Cancer diagnosis data a focus during Celebration of Research  - Thumb

Cancer diagnosis data a focus during Celebration of Research

5/25/2017

On-campus research and discovery recognized at annual event H. Gilbert Welch, MD, MPH, says there’s a problem with cancer overd... [full story]

Angiolillo receives prestigious UFRF Professorship  - Thumb

Angiolillo receives prestigious UFRF Professorship

5/17/2017

Dominick Angiolillo, MD, PhD, remains humble and appreciative after receiving one of the most revered research-based accolades given by... [full story]

Upcoming Events

Sep 12

IRB Meeting

From 12:00 PM until 2:00 PM

Sep 19

IRB Meeting

From 12:00 PM until 2:00 PM